Our results indicate a significant advantage (C-index 0.90 vs 0.64) of using the prediction model including PIRADS scores added to conventional clinic-pathological characteristics (PSA level, percentage of cancer on core-biopsies, gland size etc.)of men with prostate cancer confirmed by systematic transrectal random biopsies relative to a model without PIRADS scores. The gene discussed is KLK3; the disease is prostate cancer.